Research Interest: Biomedical research: Hartel, P. Principal Investigator. “Collection, Qualification, and Characterization of Biological Specimens for Research,” Analytic Biological Services and Davis Medical Center Clinical Trials: Fleming D, Hartel P. Multicentre, randomised, double-blind, Phase III trial to investigate the efficacy and safety of oral nintedanib plus docetaxel therapy compared to placebo plus docetaxel therapy in patients with stage IIIB/IV or recurrent, adenocarcinoma subtype non-small cell lung cancer after failure of first line chemotherapy, Boehringer Ingelheim, Protocol number 1199.128

Research Interest: Molecular Biology, Microbiology, recombinant DNA technology and biochemical methodologies.

Research Interest:  Her research showed that controlled release of growth factors accelerates neovascularization.

Research Interest: Molecular characterization of brain tumor stem cells  Therapy development for brain tumors Phase I/II Clinical Trial for malignant brain tumorsMolecular mechanism of therapy resistance of brain tumors Genetic mechanism for cell fate decisions in neural stem cells

Research Interest:  Craniofacial anomalies, biology of tooth movement, craniofacial distraction osteogenesis, dentofacial orthopedics and adult interdisciplinary treatment.

Research Interest: His current interest is in clinical research and ophthalmology

Research Interest: Magnetic Resonance Imaging/Magnetic Resonance Spectroscopy/Diffusion Tensor Imaging Osteoporosis

Research Interest: Dr Mei's research expertise is in biofilms and biomaterials. His recent research activities are mainly focused on the mechanism and prevention of bacterial adhesion and biofilm formation on dental materials.

He has measured the adhesion forces between living bacteria and orthodontic materials using atomic force microscopy at a nano-level, and decoupled the bacterial adhesion forces into specific and non-specific forces. In addition, he has investigated measures for preventing biofilm formation using quaternary ammonium compounds. He developed a novel contact-killing surface by incorporating quaternary ammonium compounds into composite resin and studied its efficacy of killing the adhered bacteria and its bio-safety for human cells.

His other interests include randomized controlled trials (RCT) and evidence-based dentistry. He has investigated clinical methods for enhancing oral hygiene in patients wearing fixed orthodontic appliances.

Research Interest: Pediatric anesthesia, neonatal anesthesia, ultrasound regional anesthesia, ultrasound pediatric and neonatal regional anesthesia, pediatric intensive care, hemodinamic monitoring, airway management, pediatric airway management, pediatric pain therapy, postoperative pain management 

Research Interest:  Osseointegration of Dental Implants / Surface modification / Bone graft Immunology of Periodontal Disease, Periodontal Disease and Systemic Conditions, Diabetes Mellitus and Periodontal Disease

Research Interest:  Currently Dr. Leiser is the head of the Laboratory for Oral Cancer Research and is supervising M.Sc. students in basic science research. Dr. Leiser specializes in surgical oncology and surgical dental rehabilitation in the maxillofacial region. The author of several scientific and clinical manuscripts in international peer-reviewed journals, he has actively participated as a lecturer in several international and national conferences in the basic sciences as well as at professional maxillofacial surgery and oncology conferences.

Research Interest: Another field of interest are the neurological manifestations linked to HTLV-1 and their pathogenesis. Dr Louboutin is currently in Jamaica trying to get a better understanding of the physiopathology of tropical spastic paraparesis/HTLV-1-associated myelopathy (TSP/HAM). The current collaboration with the Gene Therapy Program of the University of Pennsylvania is focused on gene therapy approach in different neurodegenerative disorders, (more particularly in lysosomal diseases, i.e., mucopolysaccharidosis, MPS).  Finally, Dr Louboutin is involved in cell therapy using stem cells in different tissues (i.e., bone marrow stem cells, skeletal muscle, Central Nervous System). This approach emphasizes the interaction with regenerative medicine in a translational context. Intramarrow gene delivery of SV40-derived vectors downregulating CCR5 resulted in the reduction of excitotoxin-induced seizures and their harmful consequences. These results emphasize the role of CCR5 in the immune-mediated process underlying some forms of epilepsy. He is the author of more than 80 papers in peer-reviewed journals and more than 10 book chapters

Research Interest: Neurosurgery, stem cells, brain tumors, experimental neurosurgery, brain injury,ethic, bioethic, neuroethic, medical education, biomaterials, transplant.